Prediction of flow, combustion and heat transfer in pulverised coal flames

SIGLEAvailable from British Library Document Supply Centre-DSC:DX201054 / BLDSC - British Library Document Supply CentreGBUnited Kingdo

Real-Time Incident Detection and Capacity Estimation Using Loop Detector Data

Given the fact that the existing literature lacks the real-time estimation of road capacity and incident location using data from inductance loop detectors, a data-driven framework is proposed in this study for real-time incident detection, as well as road capacity and incident location estimation. The proposed algorithm for incident detection is developed based on the variation in traffic flow parameters acquired from inductance loop detectors. Threshold values of speed and occupancy are determined for incident detection based on the PeMS database. The detection of the incident is followed by the real-time road capacity and incident location estimation using a Cell Transmission Model (CTM) based approach. The data of several incidents were downloaded from PeMS and used for the development of the proposed framework presented in this study. Results show that the developed framework detects the incident and estimates the reduced capacity accurately. The location of the incident is estimated with an overall accuracy of 92.5%. The performance of the proposed framework can be further improved by incorporating the effect of the on-ramps, off-ramps, and high-occupancy lanes, as well as by modeling each lane separately

Orthotopic administration of 213Bi-Bevacizumab inhibits progression of PC3 xenografts in the prostate

Tumour growth requires development of new blood vessels – a process known as angiogenesis. The anti-angiogenic monoclonal antibody Bevacizumab (BZ), which targets vascular endothelial growth factor (VEGF), is now part of the standard treatment for advanced colorectal cancer. Castrate resistant prostate cancers also express VEGF but are only marginally responsive to BZ alone or in combination with chemotherapy. Targeted alpha-radioimmunotherapy (TAT) is an emerging technology that can safely enhance immunotherapy for improved cancer control. TAT targeting can be further enhanced through orthotopic delivery. In this preliminary study we investigate orthotopic TAT for the control of early-stage prostate cancer PC3 xenografts using alpha radio-labelled BZ (213Bi-BZ). Results indicate that orthotopic administration of 213Bi- BZ greatly improves the early control of organ confined prostate cancer compared to BZ alone (P<0.01).JRC.E.5-Nuclear chemistr

Preclinical Studies of Bismuth-213 Labeled Plasminogen Activator Inhibitor Type 2 (PAI2) in a Prostate Cancer Nude Mouse Xenograft Model

The key objective of the study was to determine the single and multiple does toxicity and efficay of Bismuth-213 labeled PAI2 based targeted alpha therapy by selectively targeting uPA and uPAR in regressing prostate cancer in a nude mouse model.JRC.E.5-Nuclear chemistr

In Vivo and In Vitro Inhibition of Pancreatic Cancer Growth by Targeted Alpha Therapy using 213Bi-CHX.A"-C595

Purpose: The aim of this study was to investigate the effect of targeted alpha therapy for the control of in vitro pancreatic cancer cell clusters and micrometastatic cancer lesions in vivo. Methods: The expression of tumor-associated antigen MUC-1 on three pancreatic cancer cell clusters and animal xenografts was detected by indirect immmunostaining. Monoclonal antibodies C595 (test) and A2 (non-specific control) were labeled with 213Bi using the chelator CHX.A” to form the alpha-immunoconjugate (AIC). Cell clusters were incubated with AIC and examined at 48 h. Apoptosis was documented using the TUNEL assay. In vivo, an antiproliferative effect for tumors was tested at two days post-subcutaneous cell inoculation. Mice were injected with different concentrations of AIC by regional or systemic administration. Changes in tumor progression were assessed by tumor size. Results: MUC-1 is strongly expressed on CFPAC-1, PANC-1 and moderate expression was found CAPAN-1 cell clusters and tumor xenografts. The AICs can target and kill cancer cell clusters (100 mm) in vitro. Some 73–81 % of cells were TUNEL positive cells in the clusters after incubation with AIC. At two days post- cell inoculation in mice, a single local injection of 74 and 148 MBq/kg of AIC causes complete inhibition of tumor growth. Systemic injections of 111, 222 and 333 MBq/kg of AIC cause significant tumor growth delay after 16 weeks, compared with the nonspecific control providing 333 MBq/kg after 16 weeks. Conclusions: CFPAC-1, PANC-1 and CAPAN-1 pancreatic cancer cell clusters and pancreatic tumor xenografts show high expression of the MUC-1 target antigen. 213Bi-C595 can specifically target and regress pancreatic cancer cell clusters in vitro, and delay and inhibit tumor growth in vivo. 213Bi-C595 may be a useful agent for the treatment of micrometastatic pancreatic cancer with overexpression of MUC1 antigen in post-surgical patientsJRC.E.5-Nuclear chemistr

Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer

Purpose: The urokinase plasminogen activator (uPA) and its receptor (uPAR) are expressed by pancreatic cancer cells and can be targeted by the plasminogen activator inhibitor type 2 (PAI2). We have labeled PAI2 with 213Bi to form the alpha conjugate (AC), and have studied its in vitro cytotoxicity and in vivo efficacy.JRC.E.5-Nuclear chemistr

Targeted Alpha Therapy with 213 Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer.

Abstract not availableJRC.E-Institute for Transuranium Elements (Karlsruhe

Cytotoxicity of PAI2, C595 and Herceptin Vectors Labeled with the Alpha-Emitting Radioisotope Bismuth-213 for Ovarian Cancer Cell Monolayers and Clusters

The vectors PAI2, C595 and Herceptin target the membrane-bound uPA, MUCl and HER2 antigens expressed by cancer cells, respectively. The expression of these receptors was tested in the ovarian cancer cell line OVCAR-3; MUC-I was strongly expressed (3 -|->, uPA moderately expressed (2+), but HER2 was negatíveJRC.E.5-Nuclear chemistr

Control of Prostate Cancer Spheroid Growth Using (213)Bi-labeled Multiple Targeted Alpha Radioimmunoconjugates

Micrometastasis is a major problem for prostate cancer CaP patients. Our study investigated the therapeutic potential of multiple targeted alpha-therapy (MTAT) in the treatment pf CaP micrometastases (spheroids) using 213Bi-labeled multiple targeted radioimmunoconjugates.JRC.E.5-Nuclear chemistr